Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Nov 2;3(6):478-480.
doi: 10.1158/2643-3230.BCD-22-0126.

CAR T Cells Contend with Myeloma in the Bone Marrow Microenvironment

Charlotte E Graham, Marcela V Maus  1
Affiliations
Editorial

CAR T Cells Contend with Myeloma in the Bone Marrow Microenvironment

Charlotte E Graham et al. Blood Cancer Discov. .

Abstract

In this issue of Blood Cancer Discovery, Dhodapkar and colleagues find that myeloid, dendritic, and endogenous T-cell populations in the bone marrow microenvironment are associated with progression-free survival (PFS) in multiple myeloma patients responding to B-cell maturation antigen-targeted CAR T cells. Immunosuppressive myeloid cells are associated with short PFS, but a diverse T-cell receptor repertoire and more dendritic cells are associated with a longer PFS, suggesting a potential role for epitope spreading. See related article by Dhodapkar et al., p. 490 (6).

PubMed Disclaimer

Figures

Figure 1. Schematic diagram highlighting the main findings in plasma cells, hematopoietic cell lineages, and BCMA CAR T cells between responding patients with PFS <6 months or >6 months. This figure was created with Biorender. EMT, epithelial-mesenchymal transition.
Figure 1.
Schematic diagram highlighting the main findings in plasma cells, hematopoietic cell lineages, and BCMA CAR T cells between responding patients with PFS <6 months or >6 months. This figure was created with Biorender. EMT, epithelial-mesenchymal transition.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. . Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384:705–16. - PubMed
    1. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021;398:314–24. - PubMed
    1. Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. . Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2022:JCO2200842. - PMC - PubMed
    1. Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. . B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 2019;129:2210–21. - PMC - PubMed
    1. Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. . Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 2021;12:868. - PMC - PubMed

Substances